JP Morgan Downgrades Apellis Pharmaceuticals to Neutral, Raises Price Target to $41

Benzinga Newsdesk www.benzinga.com Negative 46.3%

Neg 46.3% Neu 0% Pos 0%

JP Morgan analyst Anupam Rama downgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Overweight to Neutral and raises the price target from $37 to $41.